Latest Information Update: 07 Feb 2000
At a glance
- Originator GlaxoSmithKline
- Class Antiasthmatics
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 07 Feb 2000 Discontinued-I for Asthma in United Kingdom (Inhalation)
- 24 Jun 1998 Phase-I clinical trials for Asthma in United Kingdom (Inhalation)
- 21 Apr 1998 New profile